Paul McKenzie
Paul McKenzie is the Chief Executive Officer of CSL Limited, an Australian global biotechnology company headquartered in Melbourne. Under his leadership, CSL has continued to grow, posting strong financial results and focusing on the development and distribution of life-saving medicines. McKenzie has emphasized the importance of vaccinations and public health initiatives, particularly in light of the challenges posed by vaccine skepticism in the United States. His commitment to advocating for vaccinations is crucial as CSL navigates the impact of declining vaccination rates on its flu vaccine unit, Seqirus.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| China | 1 | 8.00 | 0.05% | +0% | 1,402,112,000 | 697,221 | $14,000,000 | 6,962$ |
| Totals | 1 | 1,402,112,000 | 697,221 | $14,000,000 | 6,962$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
China:
Paul McKenzie, CEO of JetBlue, expressed his impression of China's investment in health as beneficial for global health.
8
Australia:
Paul McKenzie described CSL's half-year results as robust, with net profit rising year-on-year.
7
Australia:
Paul McKenzie described CSL's half-year results as robust, with net profit rising year-on-year.
7